ABUS
HEALTHCAREArbutus Biopharma Corp
$4.42+0.02 (+0.45%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ABUS Today?
No stock-specific AI insight has been generated for ABUS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.94$5.10
$4.42
Fundamentals
Market Cap$870M
P/E Ratio—
EPS$-0.17
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.4%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding196.9M
ABUS News
20 articles- The Zacks Analyst Blog Highlights Moderna, Merck and Vertex PharmaceuticalsYahoo Finance·May 4, 2026
- Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.Yahoo Finance·May 1, 2026
- Moderna Reports Q1 Loss, Stock Jumps on Strong International SalesYahoo Finance·May 1, 2026
- Moderna Q1 2026 earnings beat on international COVID vaccine salesQz·May 1, 2026
- Moderna sees revenue bump from international COVID vaccine salesBiopharmadive·May 1, 2026
- Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026Yahoo Finance·May 1, 2026
- Arbutus Biopharma (ABUS) Wins FDA Fast Track for ImdusiranYahoo Finance·Apr 23, 2026
- Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal ProbabilityYahoo Finance·Apr 17, 2026
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis BYahoo Finance·Apr 15, 2026
- Arbutus: Q4 Earnings SnapshotYahoo Finance·Mar 23, 2026
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 23, 2026
- Moderna Settlement And EMA Opinion Reframe mRNA Platform OutlookYahoo Finance·Mar 7, 2026
- Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle ClearsYahoo Finance·Mar 5, 2026
- Does $2.25 Billion LNP Settlement And Global License Reshape The Bull Case For Moderna (MRNA)?Yahoo Finance·Mar 4, 2026
- Why Moderna (MRNA) Stock Is Trading Up TodayYahoo Finance·Mar 4, 2026
- These Stocks Are Today’s Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and MoreYahoo Finance·Mar 4, 2026
- US Equity Markets End Higher After Strong Services, Jobs DataYahoo Finance·Mar 4, 2026
- Moderna Stock Pops After Inking $950 Million Covid Vaccine SettlementYahoo Finance·Mar 4, 2026
- Update: Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant SciencesYahoo Finance·Mar 4, 2026
- Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock.Yahoo Finance·Mar 4, 2026
All 20 articles loaded
Price Data
Open$4.45
Previous Close$4.40
Day High$4.48
Day Low$4.39
52 Week High$5.10
52 Week Low$2.94
52-Week Range
$2.94$5.10
$4.42
Fundamentals
Market Cap$870M
P/E Ratio—
EPS$-0.17
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.4%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding196.9M
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—